FTC calls out PBM price gouging of specialty generic drugs

The ability of pharmas to justify premium prices for newly developed drugs depends on those drugs one day becoming affordable generics. The FTC’s latest report shows how PBMs have sabotaged pharma companies’ ability to honor that important piece of the social contract by marking up the cost of generic medications. 

Published Tuesday by the FTC, the report is the second in a series of reports from the agency’s ongoing investigation of the PBM industry...